CompletedNot Applicable

PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma

United States120 participantsStarted 2006-01

Plain-language summary

RATIONALE: Diagnostic procedures, such as PET scan and CT scan, may help doctors determine the extent of cancer and predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying how well PET scan combined with CT scan evaluates treatment response in patients undergoing treatment for bone cancer or soft tissue sarcoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically or cytologically confirmed bone or soft tissue sarcoma * Scheduled to undergo treatment (i.e., chemotherapy and/or radiotherapy) for sarcoma * Negative pregnancy test * Fertile patients must use effective contraception * Not claustrophobic * Able to lie supine for 1 hour * Patients with diabetes mellitus allowed provided serum glucose levels ≤ 200 mg/dL Exclusion Criteria: * pregnant * other malignancies within the past 5 years (except completely resected cervical or nonmelanoma skin cancer) unless the malignancy was curatively treated and is at low risk for recurrence

What they're measuring

Determine whether device that combines fludeoxyglucose ^18F positron-emission tomography (FDG-PET) and CT scanning (FDG-PET/CT) can accurately locate and determine disease in patients who are undergoing treatment for bone or soft tissue sarcoma.

Timeframe: 6 months

Trial details

NCT IDNCT00335751

SponsorJonsson Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-07

View on ClinicalTrials.gov More Sarcoma trials